Characterization of Type II Insulin-Like Growth Factor Binding on Rat Hepatocytes of Primary Monolayer Culture : Regulation of the Binding by IGF-I and Related Peptides
スポンサーリンク
概要
- 論文の詳細を見る
Nature of insulin-like growth factor (IGF) binding on rat hepatocytes of primary monolayer culture and its regulation by IGF-related peptides were studied. The specific binding of <SUP>125</SUP>I-IGF-I to the rat hepatocytes was saturable and dependent on incubation time and temperature.<BR>The optimal pH of incubation medium was 7.8-8.2. The steady-state binding was attained at 20°C for 6h, and averaged 12% per 4×10<SUP>5</SUP> cells. Fifty percent displacement of the <SUP>125</SUP> I-IGF-I binding was observed at concentrations of 10ng/ml of IGF-I and 5 ng/ml of IGF-II, but insulin (10ng/ml-10μg/ml) did not inhibit the binding. IGF-II inhibited the binding of <SUP>125</SUP> to the hepatocytes half maximally at concentrations of 2 ng/ml. A Scatchard plot of the data of binding was linear, and indicated association constant of 1.0 X 10<SUP>9</SUP>M<SUP>-1</SUP> and a binding site of 44,000 per cell.<BR>Preincubation of the hepatocytes with either IGFs or insulin at 37°C for 24 h resulted in the reduction of <SUP>125</SUP> I-IGF-I binding to the hepatocytes in a dose-related manner, being dependent on incubation time and insulin concentrations. The binding was reduced to 20% of the control value in the presence of 10<SUP>-7</SUP>M IGF-I, and to 85% of the control in the presence of 5×10<SUP>-8</SUP>M IGF-II. Although insulin showed no affinity to the type II IGF receptors, <SUP>125</SUP> I-IGF-I binding to the hepatocytes was decreased to 60% of the control after preincubation with 10 <SUP>-10</SUP>M insulin.<BR>These results indicate that 1) the hepatocytes of primary monolayer cultures have only type II IGF binding, 2) preincubation of the cells with IGF-I, IGF-II or insulin induces the reduction of <SUP>125</SUP>I-IGF-I binding to the cells, indicating down-regulation of the binding, and 3) this binding site of rat hepatocytes is regulated by not only IGF-I and IGF-II but also insulin of physiological concentrations.
著者
-
斎藤 史郎
徳島大学医学部第一内科学教室
-
斎藤 史郎
徳島大学医学部中央臨床検査部
-
渡辺 紀明
徳島大学医学部第一内科学教室
-
山崎 正行
徳島大学医学部第一内科学教室
-
井上 利彦
徳島大学医学部第一内科学教室
-
山崎 正行
徳島大学医学部第一内科
関連論文
- プライマリ・ケア医による糖尿病合併症の調査
- 老年者高血圧症の予後調査 : 死因および心血管合併症について
- ペプチドホルモン産生異常症
- 4者 (TRH, LHRH, GHRH, CHR) 同時負荷試験による下垂体手術前後での下垂体前葉機能予備能に関する検討
- 不顕性ACTH細胞腫の4例
- Duchenne型筋ジストロフィーの女性保因者における心機能障害
- 137) アンジオテンシンI交換酵素抑制剤(SQ 14, 225)の各種高血圧症に対する臨床的応用 : 日本循環器学会第35回中国・四国地方会
- Bromocriptine (ブロモクリプチン)
- 尿崩症,本態性高ナトリウム血症 (体液--水・電解質代謝と酸・塩基平衡) -- (主要疾患における水・電解質代謝と酸・塩基平衡障害--成立機序,対策を中心に)
- ニュ-ロテンシン (脳ペプチドとその臨床) -- (脳ペプチドの神経薬理学)
- ソマトスタチン (広範囲血液・尿・化学検査--その数値をどう読むか) -- (内分泌学的検査--膵,消化管関係)
- gastric inhibitory polypeptide(GIP)〔邦文〕 (消化管ホルモンとその臨床)
- カルシトニンのラジオイムノアッセイとその臨床的応用
- Psychogenic polydipsiaとの鑑別 (Osmotic Regulation--基礎と臨床) -- (尿崩症をめぐって)
- ソマトスタチン (血液・尿・化学検査--その数値をどう読むか) -- (ホルモン)
- ペプチドホルモンのEnzyme Immunoassay (公害のない臨床検査)
- 視床下部症候群を呈し,経過中に急性腎不全を合併したHCG産生鞍上部胚芽腫の1例
- 筋肉内出血をきたし,第IX, X因子欠乏を認めた原発性アミロイドーシスの1例
- Kallmann症候群の1剖検例
- 神経性食欲不振症患者における内分泌機能と治療による影響
- Familial idiopathic basal ganglia calcification with dominant inheritance.
- Characterization of Type II Insulin-Like Growth Factor Binding on Rat Hepatocytes of Primary Monolayer Culture : Regulation of the Binding by IGF-I and Related Peptides
- ラットにおけるPGE2, 2-DGおよびL-arginineの視床下部GHRHおよびSRIFの放出に及ぼす影響とGH分泌との相関
- Amyloidoma of bone: A case report and a review of the literatures.
- Hyperimmunoglobulinemia E syndrome with deformity of bilateral fingers, juvenile cataracta and impairment of neutrophil phagocytosis.
- LH-RH
- Analysis of Leu-7+ cell subpopulation in the peripheral blood of myeloma patients
- 橋本病とバセドウ病患者におけるリンパ球の抗サイログロブリン抗体産生調節機構に関する研究
- 胃病変を主とした成人T細胞性リンパ腫の1症例
- Determination of Serum Steroid Hormones by High Performanoe Liquid Chromatography
- An autopsied case of Sjoegren's syndrome associated with IgA (.KAPPA.) monoclonal gammopathy and hypopituitarism.
- 正常者ならびに各種内分泌代謝疾患患者におけるL-dopaに対するGHRHおよびGHの分泌反応
- A New Diagnostic Significance of Determination of Serum Ornithine Carbamyltransferase for Fatty Liver